PharmaVentures increases presence in the USA

OXFORD, UK,February 10th, 2015

PharmaVentures is pleased to announce that it is to increase its presence in the North America by establishing a new base in Boston, MA, immediately.

Client News Update: Novartis enters exclusive talks on the potential sale of its UK Horsham site to the University of Brighton.

OXFORD, UK, January 27th, 2015

PharmaVentures is pleased to announce that their client Novartis has entered into exclusive negotiations with the University of Brighton on the purchase of its UK Horsham site announced on the 26th January 2015.

PharmaVentures Advises ESTEVE in Its Licensing Deal for E-58425, a New Therapeutic Product for Pain

OXFORD, UK, January 13th, 2015

PharmaVentures is pleased to announce that it has acted as advisor to ESTEVE in their successful license agreement with MundiPharma Laboratories GmbH for E-58425, a first in class NSAID/Opioid API-API co-crystal for the treatment of pain.

PharmaVentures becomes latest Partner of One Nucleus

Oxford, UK 12th January 2015

PharmaVentures has become the latest Partner to join forces with One Nucleus. Both PharmaVentures and One Nucleus are committed to playing an active and supportive role in assisting in the success of the life sciences sector nationally and internationally.


PharmaVentures Acts As Advisor to Plethora Solutions in deal with Recordati

OXFORD, UK, October 1st, 2014

PharmaVentures is pleased to announce that it has acted as advisor on deal terms to Plethora Solutions Holdings on their recently signed Licensing Agreement with Recordati to commercialise PSD502™, a novel treatment for premature ejaculation.

PharmaVentures increases its Asia-Pacific presence

OXFORD, UK, September 24th, 2014

PharmaVentures are delighted to announce that Aki von Roy has joined as an Associate, based in Auckland, New Zealand. He has over 30 years experience in Big Pharma and 16 years in biotech. He has been involved in over 18 start-up or merger ventures as director or investor. 

PharmaVentures Advises MedGenesis in Agreement with Pfizer for Its Potential Therapy for Parkinson’s Disease

OXFORD, UK, September 17th, 2014

PharmaVentures is pleased to announce that it has acted as advisor to MedGenesis Therapeutix, Inc. (MedGenesis) in their recently announced agreement with Pfizer. MedGenesis' unique therapeutic approach, which will be used in the clinical development of potential treatments for Parkinson's disease, delivers GDNF (glial cell-derived neurotrophic factor) precisely to the regions of the brain where it is required via its convection enhanced delivery (CED) technology.

PharmaVentures strengthens its expertise in early stage deal making

OXFORD, England, September 16th 2014

PharmaVentures is pleased to announce the appointment of Dr Christopher Berry, formerly of Sanofi's R&D Transactions Group, as an Associate in the corporate advisory team. Based in Paris, France, Dr Berry has negotiated 56 signed deals since 2010. Partners included universities, biotechnology companies and large pharmaceutical companies.

PharmaVentures acts as exclusive advisor on the sale of Medical Insight to Karos Health

OXFORD, UK, August 27th, 2014

PharmaVentures is pleased to announce that it acted as exclusive advisor on the sale of Medical Insight, the Danish enterprise imaging software company, to Karos Health, based in Ontario, Canada. The sale was completed in June and announced yesterday by Karos Health.

PharmaVentures Divests Manufacturing Facility for Major Pharma Client

OXFORD, UK, July 7th, 2014

PharmaVentures is pleased to announce that it has acted as advisor to one of the top 10 Pharma companies in its divestment of a manufacturing facility in North America. The deal, finalised in May, represents a significant success for the major Pharma in implementing its forward strategy and the acquisition of a growth driving capability for the acquirer. This divestment follows multiple divestments of R&D and Manufacturing facilities in the last 4 years for several of the largest pharmaceutical companies.



PharmaVentures talks to: